From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

ACE INHIBITORS DON'T ELIMINATE THE NEED FOR DIGOXIN.

It became clear in the 1980s that patients with congestive heart failure in normal sinus rhythm did worse if they stopped digitalis and took diuretics only. Now that angiotensin-converting-enzyme inhibitors are established in treating CHF, the question becomes: do patients on ACE inhibitors still need digitalis? A new study argues forcefully that they do.

The authors randomized 178 stable patients with mild-to- moderate CHF who were taking ACE inhibitors, diuretics, and digoxin to receive the first two agents plus either continued digoxin or placebo for 12 weeks. All patients were in normal sinus rhythm and had ejection fractions of 35 percent or less.

The placebo group more often developed worsening heart failure requiring study withdrawal (23 vs. 4 patients). Maximal exercise tolerance and submaximal exercise endurance remained stable with continued digoxin but decreased with placebo. The placebo group also had greater declines in New York Heart Association class, ejection fraction, and quality-of-life scores and greater increases in heart rate and body weight. Four MIs or sudden deaths occurred with digoxin versus none with placebo, a nonsignificant difference. There was one case of digitalis toxicity.

Comment: This study demonstrates convincing short-term benefits from continued use of digitalis. However, the four MIs and sudden deaths raise the question of whether digitalis has some risks. A massive long-term study now under way should settle this question.

— ALK

Published in Journal Watch General Medicine July 6, 1993

Citation(s):

Smith TW. Digoxin in heart failure. N Engl J Med 1993 Jul 1 329 51-53.

Packer M et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993 Jul 1 329 1-7.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 1993. Massachusetts Medical Society. All rights reserved.